drugset / Trial / NCT04472572

Expanded Access to Convalescent Plasma for Treatment of COVID-19

NCT04472572 ↗

Expanded access No longer available Hackensack Meridian Health

Summary

This expanded access program will provide access to investigational convalescent plasma for patients at Hackensack University Medical Center infected with SARS-CoV-2 who have severe or life-threatening COVID-19, or who are judged by a healthcare provider to be at high risk of progression to severe or life-threatening disease.

Timeline

Start
—
Primary completion
—
Completion
—

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Convalescent Plasma Protein / enzyme biologic — Other

Indications